SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-006049
Filing Date
2018-03-16
Accepted
2018-03-16 16:06:22
Documents
41
Period of Report
2018-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-10q_20180131.htm 10-Q 865050
2 EX-31.1 kalv-ex311_10.htm EX-31.1 18181
3 EX-31.2 kalv-ex312_6.htm EX-31.2 17541
4 EX-32.1 kalv-ex321_8.htm EX-32.1 8615
  Complete submission text file 0001564590-18-006049.txt   2734990

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT kalv-20180131.xml EX-101.INS 450720
6 XBRL TAXONOMY EXTENSION SCHEMA kalv-20180131.xsd EX-101.SCH 26717
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kalv-20180131_cal.xml EX-101.CAL 38793
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20180131_def.xml EX-101.DEF 47679
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20180131_lab.xml EX-101.LAB 182498
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20180131_pre.xml EX-101.PRE 132177
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 18695651
SIC: 2834 Pharmaceutical Preparations